CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Postpartum depression affects many new mothers, increasing suicide risk. New research shows preventive cognitive behavioral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

In the Vogue feature, Hidalgo opened up about how her battle with clinical depression overlapped with her wedding season.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Women who go on to develop postpartum depression (PPD) may have characteristic levels of neuroactive steroids, molecules derived from the hormone progesterone, in their blood during the third ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...